{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:15:27Z","timestamp":1758892527134,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold>The optimal management of anticoagulation in neonatal\/pediatric patients during extracorporeal membrane oxygenation (ECMO) has not been established yet and varies greatly among ECMO centers worldwide. Therefore, we aimed to assess whether the use of anti-factor Xa assay and\/or thromboelastometry correlate better than activated clotting time with heparin dose in newborns with congenital diaphragmatic hernia during ECMO. We also examined whether these coagulation assays correlate with thrombotic and\/or hemorrhagic complications, when the management of anticoagulation is based only on activated clotting time values.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>A prospective observational study in a neonatal ECMO center was conducted. We included all neonates with congenital diaphragmatic hernia born in our institution between March 2018 and January 2019 and requiring support with venoarterial ECMO. A total of 26 ECMO runs were analyzed. During the study, the heparin dose was still adjusted according to activated clotting time values. Measurements of anti-factor Xa assay, activated partial thromboplastin time, and a thromboelastometry from the same blood specimen were performed twice a day.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>Anti-factor Xa levels showed a moderate correlation with heparin dose, whereas the other tests showed a weak correlation. Four patients (17.4%) had thrombotic complications, 2 patients (8.7%) experienced life-threatening bleeding, and in 11 patients (47.8%) disseminated intravascular coagulation (DIC) occurred. Anti-factor Xa levels were lower in the group with thrombotic complications (0.23 vs. 0.27 IU\/ml;<jats:italic>p<\/jats:italic>= 0.002), while activated partial thromboplastin time was higher in the group with hemorrhagic complications (69.4 s vs. 59.8 s;<jats:italic>p<\/jats:italic>= 0.01). In patients experiencing DIC, heparin dose and anti-factor Xa levels were lower, while no difference in activated clotting time and clotting time in INTEM and INTEM-HEPTEM were shown.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold>Anti-factor Xa levels correlate better to heparin dose than activated clotting time. The use of anti-factor Xa assay instead of activated clotting time for dosing of unfractionated heparin could reduce thrombotic complications in neonates with congenital diaphragmatic hernia on ECMO support. The thromboelastometry showed no additional benefit for this purpose.<\/jats:p>","DOI":"10.3389\/fped.2021.685906","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:08:16Z","timestamp":1631858896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessing Anticoagulation in Neonates With Congenital Diaphragmatic Hernia During Extracorporeal Membrane Oxygenation: Does Anti-Factor Xa or Thromboelastometry Provide Additional Benefit?"],"prefix":"10.3389","volume":"9","author":[{"given":"Alba","family":"Perez Ortiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl E.","family":"Dempfle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thalia","family":"Doniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Hetjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schaible","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neysan","family":"Rafat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fmed.2018.00289","article-title":"Neonatal ECMO","volume":"5","author":"Van Ommen","year":"2018","journal-title":"Front Med."},{"key":"B2","first-page":"831","volume-title":"Extracorporal Life Support : The ELSO Red Book","author":"Brogan","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1097\/PCC.0b013e31827127e4","article-title":"Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey","volume":"14","author":"Bembea","year":"2013","journal-title":"Pediatric Critical Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/PCC.0000000000000028","article-title":"Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation","volume":"15","author":"Liveris","year":"2014","journal-title":"Pediatr Crit Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4068\/cmj.2017.53.2.110","article-title":"Anticoagulation therapy during extracorporeal membrane oxygenator support in pediatric patients","volume":"53","author":"Cho","year":"2017","journal-title":"Chonnam Med J."},{"key":"B6","unstructured":"ELSO anticoagulation guideline117 LequierL AnnichG Al-IbrahimO BembeaM BrodieD BroganT 34332842ELSO.2014"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fped.2016.00067","article-title":"Anticoagulation management and monitoring during pediatric extracorporeal life support: a review of current issues","volume":"4","author":"Ryerson","year":"2016","journal-title":"Front Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.thromres.2018.05.009","article-title":"Anticoagulation during ECMO in neonatal and paediatric patients","volume":"173","author":"Barton","year":"2019","journal-title":"Thromb Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fped.2019.00366","article-title":"Anticoagulation in neonatal ECMO: an enigma despite a lot of effort!","volume":"7","author":"Cashen","year":"2019","journal-title":"Front Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/PCC.0000000000000278","article-title":"The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications, and increased circuit life","volume":"16","author":"Northrop","year":"2015","journal-title":"Pediatr Crit Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/01.mat.0000247777.65764.b3","article-title":"Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation","volume":"53","author":"Nankervis","year":"2007","journal-title":"ASAIO J."},{"key":"B12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1051\/ject\/201446069","article-title":"Comparison of routine laboratory measures of heparin anticoagulation for neonates on extracorporeal membrane oxygenation","volume":"46","author":"Sulkowski","year":"2014","journal-title":"J Extra Corpor Technol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000444210","article-title":"Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium Consensus - 2015 Update","volume":"110","author":"Snoek","year":"2016","journal-title":"Neonatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/PCC.0000000000000328","article-title":"Complications during extracorporeal membrane oxygenation: why collaboration is key","volume":"16","author":"Bembea","year":"2015","journal-title":"Pediatr Crit Care Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/MAT.0b013e318279854a","article-title":"Anticoagulation monitoring during pediatric ECMO","volume":"59","author":"Bembea","year":"2013","journal-title":"ASAIO J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1309\/AJCPGVD62LKKVDLH","article-title":"Evaluation of heparin assay for coagulation management in newborns undergoing ECMO","volume":"134","author":"Khaja","year":"2010","journal-title":"Am J Clin Pathol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.athoracsur.2006.09.054","article-title":"Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival","volume":"83","author":"Baird","year":"2007","journal-title":"Ann Thorac Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1097\/PCC.0b013e31825b582e","article-title":"Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation","volume":"13","author":"Maul","year":"2012","journal-title":"Pediatr Crit Care Med."},{"key":"B19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1051\/ject\/201850149","article-title":"Use of thromboelastography to predict thrombotic complications in pediatric and neonatal extracorporeal membranous oxygenation","volume":"50","author":"Henderson","year":"2018","journal-title":"J Extra Corpor Technol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.thromres.2009.07.001","article-title":"Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support","volume":"125","author":"Alexander","year":"2010","journal-title":"Thromb Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/bja\/aeq258","article-title":"Thromboelastometry (ROTEM\u00ae) in children: age-related reference ranges and correlations with standard coagulation tests","volume":"105","author":"Oswald","year":"2010","journal-title":"Br J Anaesth."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13613-017-0352-8","article-title":"Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study","volume":"8","author":"Panigada","year":"2018","journal-title":"Ann Intensive Care."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1097\/PCC.0000000000000101","article-title":"Unfractionated heparin activity measured by anti-factor xa levels is associated with the need for extracorporeal membrane oxygenation circuit\/membrane oxygenator change: a retrospective pediatric study","volume":"15","author":"Irby","year":"2014","journal-title":"Pediatr Crit Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/0267659120952982","article-title":"Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis","volume":"36","author":"Willems","year":"2020","journal-title":"Perfusion."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.685906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T23:12:25Z","timestamp":1699485145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.685906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":24,"alternative-id":["10.3389\/fped.2021.685906"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.685906","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"article-number":"685906"}}